Professionals can also directly access courses from AAMDSIF at the Online Academy.
MDS Rounds: An AAMDSIF Visiting Faculty Program
The CME/CE-accredited MDS Rounds Program provides a forum for health care professionals who care for patients with bone marrow failure disorders to address issues related to the diagnosis and treatment of patients with myelodysplastic syndromes (MDS). Participants will learn the latest information on new therapies and advances in the management of MDS through lecture and case studies developed and presented by an expert in hematology/oncology.
Designed for a standard one-hour program format, this program has been developed by the Aplastic Anemia and MDS International Foundation (AAMDSIF) and accredited by USF Health. It is available at no charge for medical centers to provide for their professional staff.
Advances in Treating MDS and Related Bone Marrow Failure Diseases: The Role of Nurses in Managing Therapy and Personalizing Care
Breakfast Symposium at ONS Annual Congress in Denver, CO
6:00 – 7:30 am, Hyatt Regency Denver, Centennial F-G
This CE-certified program will provide participants with the latest informatio on the pathophysiology and differential diagnosis of MDS and related bone marrow failure diseases; risk and prognostic scoring systems; treatment options for low-risk and high-risk MDS, AML, and MDS/MPN overlap; disease management; and ways to address psychosocial and quality-of-life issues to improve the care of this patient population.
Registration opening soon.
Regional Bone Marrow Failure Disease Symposia
Clinicians caring for both children and adults are frequently faced with patients with low blood counts and the challenge of initial management and work-up. This symposium will provide participants with the most up-to-date review of scientific and clinical research related to the biology and management of pediatric and adult bone marrow failure diseases, including anemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and paroxysmal nocturnal hemoglobinuria (PNH). The presenters will focus on the latest advances in the diagnosis, genetic characteristics, pathology and treatment options for these diseases, including the importance of recognizing adult presentations of inherited marrow failure syndromes and recent discoveries in inherited bone marrow failure defects.
2017 dates and locations to be announced.
Milwaukee, Wisconsin - November 4, 2016
Cosponsored with Medical College of Wisconsin
Portland, Oregon - September 14, 2016
Cosponsored with Oregon Health and Science University
Clinical Management of MDS/MPN: A Mountain of Evidence for Treatment Selection in MDS/MPN
CME-certified Satellite Lunch Symposium, preceding the 58th ASH Annual Meeting
Plan to attend the symposium that will provide an in-depth and up-to-date review of research related to the biology, prognosis, natural history, and therapeutic management of patients with MDS, MPN and MDS/MPN overlap.
Register Today! ccfcme.org/MDS16
International Scientific Symposium 2016
Video Interviews with Session Leaders
- The Genetics of Bone Marrow Failure
- Transplant Treatments for Bone Marrow Failure
- The Immunology of Bone Marrow Failure Disease
- Pathophysiology and New Molevular Targets of Bone Marrow Failure
- Non-Transplant Options for Aplastic Anemia and PNH
- Non-Transplant Treatment Options for MDS
- Transplant and Treatment for Older Patients with Aplastic Anemia
- Diagnosis of Bone Marrow Failure in the Genomics Era
- Cutting Edge Approaches to Treating Aplastic Anemia
Assessing Anemia in Older Patients and When to Suspect MDS
AA&MDSIF is committed to providing quality and timely educational activities for community hematologists/oncologists, gerontologists, and primary care physicians. This webcast is a studio-based discussion between an academic-based hematologist/oncologist specializing in MDS and a community-based oncologist. These two professionals discuss cases to review the evaluation and work-up of anemia and cytopenias seen in general practice and to review symptoms, clinical presentations, treatment options and post-diagnosis issues common within MDS.
B. Douglas Smith, MD, Professor of Oncology and Eric J. Seifter, MD, Associate Professor of Medicine and Oncology, Johns Hopkins University School of Medicine
Upon completion of this program, viewers will be able to
- Identify the symptoms that in conjunction with anemia, should lead to suspected MDS
- Discuss diagnostic techniques, including bone marrow biopsy
- Review treatment options for patients with MDS, including supportive care, and assistant in the development of appropriate treatment goals for MDS patients
- Understand how immunomodulatory drugs work against MDS
- Be familiar with benefits, safety margins, and adverse effects of medications used to treat MDS
Part 1: Diagnosing MDS
Part 2: MDS Diagnostic Workup, Staging and Supportive Therapy
Part 3: Beyond Supportive Therapies
ONS Congress Satellite Symposium
Enhancing the Oncology Nurse's Role in MDS Patient Communication and Education
This breakfast symposium at the 2015 ONS Annual Congress focused on the role of the oncology nurse in shared decision-making with myelodysplastic syndromes (MDS) patients. Topics include treatment options for low-risk and high-risk MDS, the impact of comorbidities and psychosocial factors in therapy choices, and communication techniques for nurses to use for patient education and treatment management. Case studies were be used to illustrate the challenges of monitoring MDS and adapting therapy to improve outcome and quality of life for patients.
- Joan Latsko, DNP, CRNP, AOCNP, Innovative Wellness Solutions, Pittsburgh, PA
- Leslie Pettiford, RN, BSN, CCRC, University of Florida Health Center, Gainesville, FL
- Christa Roe, RN, BSN, OCN, Moffitt Cancer Center
ONS Congress Satellite Symposia
- 2016 - Latest Developments in Treating MDS
- 2015 - Enhancing the Oncology Nurse's Role in MDS Patient Communication and Education
MDS and MDS/MPN: Past, Present, and Future - recorded at American Society of Hematology Annual Meeting 2014
This webcast features disease research and clinical practice to review the contributions of cytogenetics and molecular genetics to the biology of myelodysplastic syndromes and the overlap disease myelodysplastic syndromes/myeloproliferative neoplasms. Also identified is the role of novel pharmacologic therapies and innovations with transplantation to improve the care of these patient populations.
Treatment Decision-Making Through the Spectrum of MDS
Explaining MDS to patients can be challenging for healthcare professionals. The disease process is complex, the prognosis variable, and treatment options must be tailored for each patient. This series of three continuing education programs - one each for low risk MDS, high risk MDS, and stem cell transplantation - focuses on effective communication to ensure optimal outcomes when managing patients with MDS.
The target audience for these programs is oncologists, hematologists, oncology nurses, and other healthcare providers who diagnose and manage MDS patients.
Each program provides 0.5 CE credit.
Current Perspectives of MDS: The Role of the Oncology Nurse in Treatment Management and Patient Education
This program, a recording of the AA&MDSIF Satellite Symposium at the 2014 ONS Annual Congress, focuses on the current perspectives of MDS, including the disease biology, diagnostic evaluation and treatment options for low-risk and high-risk MDS, and the nurse's role in managing treatment and educating patients and caregivers. The goals of this activity are to update participants on the therapies available for MDS patients, discuss the impact of comorbidities and psychosocial factors in disease management, and improve the care for this patient population. Case studies are incoporated to explain the challenges of monitoring the disease and adapting therapy to improve outcome and quality of life for MDS patients.
This program has been approved for 1.5 contact hours by the ONS Approver Unit. ONS is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
A Discussion of the Management of Patients with Myelodysplastic Syndromes
Three physicians with extensive experience treating patients with myelodysplastic syndromes (MDS) discuss the challenges in its diagnosis and management. The conversation covers classification and identification of low risk and high risk MDS, standard treatments, refractory MDS, and how they discuss treatment options with these patients and their caregivers.